Category: BioTech

Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

FWRD 2Q Consolidated Revenue Increased

Forward Air’s FWRD second-quarter consolidated revenue increased 8% but was roughly flat when excluding the addition of TQI, which was acquired in March. The core airport-to-airport business fell 5% from last year, driven by 3% deterioration in total yield and a low-single-digit fall in tonnage. A large portion of the revenue decline relates to a previously announced customer loss ($6 million impact). Forward Air Solutions … Continue reading FWRD 2Q Consolidated Revenue Increased

Jason KnoxLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

STO Second Quarter Production Has Modest Rise

Santos’s second-quarter production rose 2% to 12.4 million barrels of oil equivalent (mmboe), marginally below expectations, and full-year 2013 production guidance has been reduced by 3% to between 52 and 55 mmboe. The decline reflects deferred oil and gas production from Chim Sao in Vietnam due to power system constraints, steeper than- expected natural field decline at Sangu, and deferred Carnarvon production due to poor … Continue reading STO Second Quarter Production Has Modest Rise

Ryan HoltzLeave a comment
BioTech, Finance

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading

Richard Atkins
BioTech, Finance

Major Biotech Stock in News: Amgen Files Blinatumomab Marketing Application

Amgen (AMGN) announced that it has submitted a Biologics License Application (BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). The BLA includes positive data from a phase II study which evaluated the use of blinatumomab in adults with Ph- relapsed/refractory … Continue reading Major Biotech Stock in News: Amgen Files Blinatumomab Marketing Application

Richard Atkins
Biotech Finance News
BioTech, Finance

Biotech Stock Gilead Down Due To Weak Data Results

Shares of Gilead Sciences (GILD) declined approximately 0.9% to close the trading session on Sep 17 at $103.84 following a couple of setbacks — the failure of an oncology candidate to meet the primary endpoint in a phase II study and highly concerning data on the company’s blockbuster hepatitis C drug Sovaldi. Gilead’s pipeline candidate simtuzumab in combination with Eli Lilly and Company’s (LLY) Gemzar … Continue reading Biotech Stock Gilead Down Due To Weak Data Results

Richard Atkins
Biotech Stock
BioTech, Finance

Active Stock in News: Bayer/Regeneron Successfully Expand Eylea Label

The HealthCare segment at Bayer (BAYRY) announced that its blockbuster eye treatment, Eylea, was approved for yet another indication in Japan. The drug was approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of myopic choroidal neovascularization (myopic CNV). Eylea’s approval in the myopic CNV indication was based on encouraging results from the phase III MYRROR study. The drug … Continue reading Active Stock in News: Bayer/Regeneron Successfully Expand Eylea Label

Richard Atkins